Skip to main content

Table 1 Demographic and clinical characteristics

From: Metabolic and cardiorespiratory effects of decreasing lung hyperinflation with budesonide/formoterol in COPD: a randomized, double-crossover, placebo-controlled, multicenter trial

Characteristics

Total (N = 51)

Demographica

Age, mean (SD), y

62.9 (8.32)

Women, n (%)

24 (47)

BMI, mean (SD), kg/m2

28.02 (6.88)

Race, n (%)

 White

37 (72.5)

 African American

13 (25.5)

 Other

1 (2.0)

Clinicalb,c

 IC, L

1.934 (0.526)

   Change after administration of BUD/FORM

0.367 (0.169)

 FEV1, L

1.147 (0.366)

  Change after administration of BUD/FORM

0.191 (0.114)

 FVC, L

2.497 (0.802)

  Change after administration of BUD/FORM

0.308 (0.218)

 FEV1/FVC

0.472 (0.097)

  Change after administration of BUD/FORM

0.017 (0.036)

 TLC, L

6.214 (1.221)

 FRC, L

4.314 (1.018)

  1. BMI body mass index, BUD/FORM budesonide/formoterol, FEV1 forced expiratory volume in 1 s, FRC functional residual capacity, FVC forced vital capacity, IC inspiratory capacity, SD standard deviation, TLC total lung capacity
  2. aAt baseline
  3. bAt screening
  4. cAll values reported as mean (SD)